Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia | Zendy

Ignacio MartínLoeches | Zendy; JeanFrançois Timsit | Zendy; Marin H. Kollef | Zendy; Richard G. Wunderink | Zendy; Nobuaki Shime | Zendy; Martin Nováček | Zendy; Ülo Kivistik | Zendy; Álvaro Réa-Neto | Zendy; Christopher Bruno | Zendy; Jennifer A. Huntington | Zendy; Gina Lin | Zendy; Erin Jensen | Zendy; Mary Motyl | Zendy; Brian Yu | Zendy; Davis Gates | Zendy; Joan R. Butterton | Zendy; Elizabeth G. Rhee | Zendy

Open Access

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Author(s) -

Ignacio MartínLoeches,

JeanFrançois Timsit,

Marin H. Kollef,

Richard G. Wunderink,

Nobuaki Shime,

Martin Nováček,

Ülo Kivistik,

Álvaro Réa-Neto,

Christopher Bruno,

Jennifer A. Huntington,

Gina Lin,

Erin Jensen,

Mary Motyl,

Brian Yu,

Davis Gates,

Joan R. Butterton,

Elizabeth G. Rhee

Publication year - 2021

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkab494

Subject(s) - meropenem , medicine , tazobactam , hospital acquired pneumonia , pneumonia , ventilator associated pneumonia , population , klebsiella pneumoniae , microbiology and biotechnology , pseudomonas aeruginosa , bacterial pneumonia , antibiotics , biology , antibiotic resistance , bacteria , escherichia coli , biochemistry , genetics , environmental health , imipenem , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research